About Arch Therapeutics
Arch Therapeutics is a company based in Natick (United States) founded in 2006. Arch Therapeutics has raised $320 thousand across 13 funding rounds. Arch Therapeutics offers products and services including AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G. Arch Therapeutics operates in a competitive market with competitors including Abyrx, Biom'Up, Prytime Medical Devices, Endomedix and United Health Products, among others.
- Headquarter Natick, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website archtherapeutics.com
- Social LinkedIn X Facebook
- Legal Name Arch Therapeutics Inc
- Annual Revenue$75.72 K (USD)383.8as on Sep 30, 2023
- Net Profit-$6.98 M (USD)-32.35as on Sep 30, 2023
- EBITDA-$5.04 M (USD)11.62as on Sep 30, 2023
- Total Equity Funding$320K (USD)
in 13 rounds
Products & Services of Arch Therapeutics
Arch Therapeutics offers a comprehensive portfolio of products and services, including AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G.
Self-assembling technology for managing wounds in surgery and trauma.
Product to control bleeding during medical procedures.
Agent for gastrointestinal bleeding and submucosal lifting.
Funding Insights of Arch Therapeutics
Arch Therapeutics has successfully raised a total of $320K across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $320,000
- Total Rounds 13
- First Round $245,000
(Jun 2007)
Latest 10 of 13 funding rounds of Arch Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | – | Post-IPO | – | – | – |
| Jul 2022 | $3.5M | Post-IPO | – | – | – |
| Feb 2021 | $6.9M | Post-IPO | – | – | – |
| Nov 2020 | $1.1M | Post-IPO | – | – | – |
| Jun 2020 | $1.4M | Post-IPO | – | – | – |
| May 2016 | $3.4M | Post-IPO | – | – | – |
| Jun 2015 | $3.07M | Post-IPO | – | – | – |
| Mar 2015 | $750,000 | Post-IPO | – | – | – |
| Feb 2014 | $2.85M | Post-IPO | – | – | – |
| Jul 2013 | $7.32M | Post-IPO | – | – | – |
People of Arch Therapeutics
18 people are tracked at Arch Therapeutics (4 in leadership, 14 in board & advisors).
| Name | Role | Group |
|---|---|---|
Michael Abrams | CFO | Leadership |
Richard E. Davis | Chief Financial Officer | Leadership |
Chirag B. Shah | VP of R&D Engineering & Quality Systems | Leadership |
Terrence W. Norchi | Chairman, President & CEO | Leadership |
Elaine Whitmore | Regulatory Consultant, Advisor | Board & advisors |
Punit Dhillon | Director | Board & advisors |
Avtar Dhillon | Business Advisor | Board & advisors |
Larry Hicks | Business Advisor | Board & advisors |
John Richards | Business Advisor | Board & advisors |
Shri Parikh | Advisor | Board & advisors |
William T. Denman | Clinical Advisor | Board & advisors |
Rutledge Ellis-Behnke | Scientific Advisor & Co-Founder | Board & advisors |
Daniel Kapp | Clinical Advisor, Wound Care & Plastic Surgery | Board & advisors |
Roger Gregory | Scientific Advisor | Board & advisors |
William G. Austen | Clinical Advisor, Wound Care & Plastic Surgery | Board & advisors |
Steven A. Kates | Scientific Advisor | Board & advisors |
Steve Schwaitzberg | Clinical Advisor | Board & advisors |
James Sulat | Director | Board & advisors |
Complete people profiles for Arch Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Arch Therapeutics
Arch Therapeutics is a publicly listed company on the OTC with ticker symbol ARTHQ in USA, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 May 2013
- Listed onOTCMKTS: ARTH
- Listed entityARCH THERAPEUTICS INC
- Exchange sectorDistribution services
- ISINUS03939W2089
- Share price$0.00 (-99% on the day) · 2026-01-05
- Market capitalisation$4.44
- Volume (last session)845
- Analyst consensusNeutral
Financials of Arch Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | $75,720 | -$7.0M | -$5.0M |
| 2022 | $15,650 | -$5.3M | -$5.7M |
| 2021 | $11,560 | -$6.2M | -$6.4M |
| 2020 | – | -$4.7M | -$5.3M |
Detailed financial statements for Arch Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Arch Therapeutics
4 dated milestones of Arch Therapeutics across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Arch Therapeutics is founded.
- Funding First funding round of $245K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Arch Therapeutics
Arch Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abyrx, Biom'Up, Prytime Medical Devices, Endomedix and United Health Products, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abyrx.com | 2013 | Irvington, United States | $10M | – | Hemostatic bone putty is developed for surgical bone bleeding control. | |
| biomup.com | 2005 | Saint Priest Bramefant, France | $43.82M | – | Hemostatic products for surgical applications are developed using collagen-based materials. | |
| prytimemedical.com | 2011 | Boerne, United States | $10M | 41 | Developer of minimally invasive large vessel occludes for hemorrhage control in trauma patients | |
| endomedix.com | 2005 | Newark, United States | $1.99M | – | Hydrogel solutions for surgery and wound care are developed. | |
| uhpcorp.com | 1997 | Mesquite, United States | – | – | Medical device for hemostasis during surgical procedures is provided. | |
| life-bond.com | 2007 | Caesarea, Israel | $56.5M | – | Absorbable surgical sealants and hemostats are developed for leakage prevention. | |
| obsidiomed.com | 2018 | Solana Beach, United States | $3M | – | Shear-thinning biomaterial is developed to control blood flow minimally invasively. | |
| fusionmed.com | 1992 | Fremont, United States | – | – | Collagen-derived particles and thrombin are utilized for surgical hemostasis. | |
| surgrx.com | 2001 | Redwood, United States | $62.5M | – | Tissue sealing and hemostasis systems are developed for laparoscopic surgery. |
Detailed competitors of Arch Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arch Therapeutics
The website of Arch Therapeutics (archtherapeutics.com) receives about 1.7K visits a month and ranks #7,558,673 among all websites worldwide, #7,062 in Biotechnology and Pharmaceuticals.
- Monthly visits1.7K
▼ 3.5% vs previous month
- Global rank#7,558,673
among all websites
- Category rank#7,062
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit2.5
- Average visit45 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Arch Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| athersys.com | 100% | 1.7K | #8,716,189 | View details | |
pharmaceuticals.einnews.com | pharmaceuticals.einnews.com | 99% | – | – | – |
| medibid.com | 58% | – | #7,854,289 | View details | |
wilsonssyndrome.com | wilsonssyndrome.com | 58% | – | #6,935,104 | – |
cancercouncil.com.au | cancercouncil.com.au | 58% | – | #220,638 | – |
Latest news on Arch Therapeutics
Complete news archive for Arch Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Arch Therapeutics
10 companies that operate in the same segment as Arch Therapeutics (Medical Equipment & Supplies), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Software and integrated solutions for surgical and radiotherapy applications | 1989 | Munchen, Bayern, Germany | USD 12.68 M | USD 1.18 M | 18 | |
Robotic waterjet system for prostate tissue removal is developed. | 2009 | Redwood City, California, United States | USD 348.84 M | USD 308.05 M | 756 | |
Collaborative surgical robotic systems are provided for hospital procedures. | 2014 | Cambridge, Cambridgeshire, United Kingdom | USD 1.32 B | – | – | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.17 M | – | 242 | |
Augmented reality systems for guiding surgical procedures are developed. | 2014 | Yokneam Illit, North District, Israel | USD 142.6 M | – | – | |
Manufacturer of imaging and surgical products | 1919 | Tokyo, Tokyo, Japan | – | USD 6.49 B | 35,933 | |
Injectable packaging, containment, and delivery solutions are manufactured. | 1923 | Exton, Pennsylvania, United States | – | USD 3.07 B | 10,600 | |
Rapid infusion systems are provided for critically ill patients. | 2012 | Durham, North Carolina, United States | USD 77.98 M | – | – | |
Mobile robots are manufactured for industries including healthcare and agriculture. | 2013 | Odense, Denmark | USD 81.44 M | – | 303 | |
Visualization systems for surgical procedures are developed using machine learning. | 2016 | Seattle, Washington, United States | USD 74.25 M | – | 52 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Arch Therapeutics
Arch Therapeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Arch Therapeutics is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
Arch Therapeutics is a funded company, having raised a total of $320K across 13 funding rounds to date. The company's 1st funding round was a Post-IPO of $7.32M, raised on Jun 2007.
Annual revenue of Arch Therapeutics is $75.72K as on Sep 30, 2023.
Arch Therapeutics was founded in 2006 and is headquartered in Natick, United States. Operations center on biotechnology, with development of a synthetic peptide-based hemostatic device known as AC5 for use in minimally invasive and open surgical procedures. The transparent, biocompatible material is applied to achieve rapid bleeding control and fluid leakage prevention, particularly in irregular wound sites. As of January 2016, human trials had not been conducted.
Arch Therapeutics's top competitors include Prytime Medical Devices, Biom'Up and United Health Products.
Arch Therapeutics offers AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G.
Yes, Arch Therapeutics is publicly traded on OTC under the ticker symbol ARTHQ.
Arch Therapeutics operates through Arch Therapeutics, Inc..